Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2015 Feb;15(2):157-64. doi: 10.1586/14737140.2015.974563. Epub 2014 Nov 29.

A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands.

Author information

1
Department of Pediatrics, Division of Oncology/Hematology, VU University Medical Center, De Boelelaan 1118, Room KTC4.027, 1081 HZ Amsterdam, The Netherlands.

Abstract

INTRODUCTION:

Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clinical research, a prerequisite for increasing the chance to find a cure.

METHODS:

We performed a population-based retrospective cohort study by evaluating all children diagnosed with DIPG in the Netherlands between 1990 and 2010.

RESULTS:

The incidence of DIPG in the Netherlands corresponds with international literature. Between 1990 and 2010, a large heterogeneity of treatment schedules was applied and only a minority of patients was included in clinical trials.

DISCUSSION:

Given the rarity of DIPG, we emphasize the need for (inter-)national trials to facilitate the identification of potentially effective therapeutics in the future. This can be supported by the recent development of a European DIPG registry enabling international study collaborations.

KEYWORDS:

brainstem tumor; chemotherapy; clinical trial; diffuse intrinsic pontine glioma; high-grade glioma; pediatric oncology; radiotherapy; treatment

PMID:
25435089
DOI:
10.1586/14737140.2015.974563
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center